{"id":"NCT02072824","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.","officialTitle":"A Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Of The Efficacy And Safety Of Pregabalin As Adjunctive Therapy In Children 1 Month Through <4 Years Of Age With Partial Onset Seizures","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-09-16","primaryCompletion":"2018-03-13","completion":"2018-03-13","firstPosted":"2014-02-27","resultsPosted":"2018-10-09","lastUpdate":"2021-01-20"},"enrollment":175,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Onset Seizures"],"interventions":[{"type":"DRUG","name":"Pregabalin Dose Level 1","otherNames":[]},{"type":"DRUG","name":"Pregabalin Dose Level 2","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Study Drug Level 1","type":"EXPERIMENTAL"},{"label":"Study Drug Level 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is designed to evaluate the effectiveness of 2 doses of pregabalin to reduce seizure frequency as an add on therapy in pediatric subjects 1 month to \\<4 years of age with refractory partial onset seizures. It is hypothesized that both doses of pregabalin will demonstrate superior efficacy when compared to placebo by reducing the partial onset seizure frequency and that pregabalin will be safe and well tolerated.","primaryOutcome":{"measure":"Log Transformed 24-Hour Seizure Rate for All Partial Onset Seizures During the Double-Blind Treatment Phase","timeFrame":"Day 1 up to Day 14","effectByArm":[{"arm":"Pregabalin 7 mg/kg/Day or 6 mg/kg/Day","deltaMin":1.69,"sd":0.115},{"arm":"Pregabalin 14 mg/kg/Day or 12 mg/kg/Day","deltaMin":1.15,"sd":0.163},{"arm":"Placebo","deltaMin":1.58,"sd":0.129}],"pValues":[{"comp":"OG000 vs OG002","p":"0.4606"},{"comp":"OG001 vs OG002","p":"0.0223"}]},"eligibility":{"minAge":"1 Month","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":6},"locations":{"siteCount":72,"countries":["United States","Belarus","Belgium","Bosnia and Herzegovina","Bulgaria","China","France","Germany","Greece","Hungary","Israel","Lebanon","Malaysia","Philippines","Romania","Russia","Serbia","South Korea","Spain","Taiwan","Thailand","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["32189338"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081042&StudyName=A%20Safety%2C%20Efficacy%2C%20and%20Tolerability%20Trial%20of%20Pregabalin%20as%20Add-On%20Treatment%20in%20Pediatric%20Subjects%20%3C4%20years%20of%20age%20with%20Partial%20"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":71},"commonTop":["Somnolence","Upper respiratory tract infection","Pyrexia","Vomiting","Nasopharyngitis"]}}